Perceptive funds disclose Yarrow Bioscience (YARW) pre-funded warrant stake
Rhea-AI Filing Summary
Perceptive Life Sciences Master Fund Ltd, Perceptive Advisors LLC and Joseph Edelman, each reported as a 10% owner of Yarrow Bioscience, Inc., disclose initial indirect holdings of 967,360 shares of Common Stock via immediately exercisable, non-expiring Pre-Funded Warrants at an exercise price of $0.0001 per share and 266,309 shares of Common Stock.
The warrants are subject to a 9.99% Beneficial Ownership Limitation that currently prevents any exercise, and Perceptive Advisors and Mr. Edelman disclaim beneficial ownership except for their indirect pecuniary interest in the Master Fund.
Positive
- None.
Negative
- None.
Insider Trade Summary
2 transactions reported
Mixed
2 txns
Insider
PERCEPTIVE ADVISORS LLC, PERCEPTIVE LIFE SCIENCES MASTER FUND LTD, EDELMAN JOSEPH
Role
10% Owner | 10% Owner | 10% Owner
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Pre-Funded Warrant (right to buy) F2, F1 | -- | -- | -- |
| holding | Common Stock F1 | -- | -- | -- |
Holdings After Transaction:
Pre-Funded Warrant (right to buy) — 967,360 shares (Indirect, See Footnote);
Common Stock — 266,309 shares (Indirect, See Footnote)
Footnotes (2)
- F1. The securities are directly held by Perceptive Life Sciences Master Fund, Ltd. (the "Master Fund"). Perceptive Advisors LLC (the "Advisor") serves as the investment manager of the Master Fund. Joseph Edelman ("Mr. Edelman") serves as the managing member of the Advisor. Each of Mr. Edelman and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of their indirect pecuniary interest therein, and this report shall not be deemed an admission that the Advisor or Mr. Edelman is a beneficial owner of such securities for purposes of Section 16 or for any other purpose.
- F2. The Pre-Funded Warrants are immediately exercisable and do not expire. The terms of the Pre-Funded Warrants provide that such warrants may not be exercised if, after such exercise, the Reporting Persons would beneficially own, as determined in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended, more than 9.99% of the shares of Common Stock then issued and outstanding after giving effect to such exercise (the "Beneficial Ownership Limitation"). As of the date hereof, the Beneficial Ownership Limitation does not permit the Master Fund (as defined herein) to exercise any of its Warrants.
Key Figures
Pre-Funded Warrant underlying shares: 967,360 shares
Common Stock held: 266,309 shares
Pre-Funded Warrant exercise price: $0.0001 per share
+1 more
4 metrics
Pre-Funded Warrant underlying shares
967,360 shares
Underlying Common Stock for Pre-Funded Warrants reported as of 2026-07-27
Common Stock held
266,309 shares
Indirectly held by Perceptive Life Sciences Master Fund Ltd as of 2026-07-27
Pre-Funded Warrant exercise price
$0.0001 per share
Exercise price of Pre-Funded Warrants for Yarrow Bioscience Common Stock
Beneficial Ownership Limitation
9.99%
Maximum beneficial ownership allowed after warrant exercise under warrant terms
Key Terms
Pre-Funded Warrant (right to buy), Beneficial Ownership Limitation, indirect pecuniary interest, Section 16 of the Securities Exchange Act of 1934
4 terms
Pre-Funded Warrant (right to buy) financial
"Security title reported as Pre-Funded Warrant (right to buy) for indirect holdings"
Beneficial Ownership Limitation regulatory
"The terms of the Pre-Funded Warrants provide a 9.99% Beneficial Ownership Limitation"
A beneficial ownership limitation is a rule that caps the percentage of a company’s shares an investor can be treated as owning or controlling for voting, regulatory or tax purposes. It matters to investors because it can restrict how many shares a person or group can buy or vote, affect takeover chances, and influence share liquidity and value — like a speed limit that prevents any single driver from taking over the whole road.
indirect pecuniary interest regulatory
"Advisor and Mr. Edelman disclaim beneficial ownership except to their indirect pecuniary interest"
Section 16 of the Securities Exchange Act of 1934 regulatory
"Disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership"
A provision of federal securities law that requires company insiders—directors, officers and large shareholders—to publicly report their stock holdings and trades and to surrender any “short-swing” profits from purchases and sales within a six-month window. It acts like a rule that forces leaders to announce their trades and prevents quick buy-sell windfalls, giving investors transparency into insider activity and reducing opportunities for unfair gain.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
Who are the reporting persons in this Yarrow Bioscience (YARW) Form 3 that VYNE followers might track?
The Form 3 lists Perceptive Life Sciences Master Fund Ltd, Perceptive Advisors LLC and Joseph Edelman as reporting persons, each reported as a 10% owner in connection with indirect holdings of Yarrow Bioscience, Inc. common stock and pre-funded warrants.
What positions are reported for Yarrow Bioscience (YARW) in this Form 3?
The filing reports indirect holdings of 967,360 shares of Common Stock through Pre-Funded Warrants and 266,309 shares of Common Stock held by Perceptive Life Sciences Master Fund Ltd, with Perceptive Advisors and Joseph Edelman linked through their investment management roles.
What is the 9.99% Beneficial Ownership Limitation described for Yarrow Bioscience (YARW)?
The Pre-Funded Warrants include a 9.99% Beneficial Ownership Limitation, meaning they cannot be exercised if doing so would cause the reporting persons to beneficially own more than 9.99% of Yarrow’s outstanding common shares, and currently this cap does not permit any warrant exercise.
Are the Yarrow Bioscience Pre-Funded Warrants immediately exercisable and do they expire?
The Pre-Funded Warrants are described as immediately exercisable and do not expire. However, their exercise is restricted by the 9.99% Beneficial Ownership Limitation, which as of the reporting date prevents the Master Fund from exercising any of its warrants despite their exercisability.
Does this Yarrow Bioscience (YARW) Form 3 show new buying or selling activity relevant to VYNE investors?
No buy or sell transactions are reported. The Form 3 presents initial beneficial ownership positions, listing indirect holdings of common stock and pre-funded warrants by the Master Fund, without any transaction codes, share amounts bought or sold, or prices indicating recent trading activity.
How do Perceptive Advisors and Joseph Edelman describe their ownership of Yarrow Bioscience securities?
The securities are directly held by the Master Fund, for which Perceptive Advisors is investment manager and Joseph Edelman is managing member. Both disclaim beneficial ownership for Section 16 purposes, except to the extent of their indirect pecuniary interest in the Master Fund.